Racial/Ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus

Current Medical Research and Opinion

Volumn 31, Issue 5, 2015, Pages 913-923

  Ferdinand, Keith C ^a   Nasser, Samar A ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Ethnicity; Insulin; Racial disparities in access to treatment; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ALOGLIPTIN; ANTIDIABETIC AGENT; BROMOCRIPTINE; CANAGLIFLOZIN; COLESEVELAM; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; VOGLIBOSE;

AFRICAN; AFRICAN AMERICAN; AMERICAN; ASIAN; CARDIOVASCULAR DISEASE; CLINICAL STUDY; COMORBIDITY; DISEASE CONTROL; DRUG RELEASE; EDUCATION PROGRAM; EPIDEMIOLOGICAL DATA; ETHNIC GROUP; ETHNICITY; HEALTH DISPARITY; HISPANIC; HUMAN; HYPERTENSION; KIDNEY FAILURE; MINORITY GROUP; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT EDUCATION; PREVALENCE; RACE; REVIEW; RISK FACTOR; ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; HEALTH CARE DISPARITY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; ETHNIC GROUPS; HEALTHCARE DISPARITIES; HUMANS; HYPOGLYCEMIC AGENTS; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 84928197069     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1029894     Document Type: Review

References (75)

1. National Diabetes Statistics Report, 2014. Centers for Disease Control and Prevention (CDC). 2014. Available at: http://www.cdc.gov/diabetes/pubs/ statsreport14/national-diabetes-report-web.pdf [Last accessed 27 January 2015]
2. National Prevention Strategy. US Department of Health and Human Services. 2011. Available at: http://www.surgeongeneral.gov/initiatives/prevention/ strategy/report.pdf [Last accessed 27 January 2015]
3. Ford ES. Trends in predicted 10-year risk of coronary heart disease and cardiovascular disease among U.S. adults from 1999 to 2010. J Am Coll Cardiol 2013;61:2249-52
4. Gregg EW, Zhuo X, Cheng YJ, et al. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study. Lancet Diabetes Endocrinol 2014;2:867-74
5. Karlamangla AS, Merkin SS, Crimmins EM, Seeman TE. Socioeconomic and ethnic disparities in cardiovascular risk in the United States, 2001-2006. Ann Epidemiol 2010;20:617-28
6. Meyer PA, Yoon PW, Kaufmann RB; Centers for Disease Control and Prevention (CDC). Introduction: CDC Health Disparities and Inequalities Report-United States, 2013. MMWR Surveill Summ 2013;62(Suppl 3):3-5
7. Liu J, Hickson DA, Musani SK, et al. Dietary patterns, abdominal visceral adipose tissue, and cardiometabolic risk factors in African Americans: the Jackson heart study. Obesity (Silver Spring) 2013;21:644-51
8. Okosun IS, Annor F, Dawodu EA, Eriksen MP. Clustering of cardiometabolic risk factors and risk of elevated HbA1c in non-Hispanic White, non-Hispanic Black and Mexican-American adults with type 2 diabetes. Diabetes Metab Syndr 2014;8:75-81
9. Burrows NR, Li Y, Williams DE. Racial and ethnic differences in trends of endstage renal disease: United States, 1995 to 2005. Adv Chronic Kidney Dis 2008;15:147-52
10. Kirk JK, D'Agostino Jr RB, Bell RA, et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a metaanalysis. Diabetes Care 2006;29:2130-6
11. Kirk JK, Passmore LV, Bell RA, et al. Disparities in A1C levels between Hispanic and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care 2008;31:240-6
12. Herman WH, Ma Y, Uwaifo G, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007;30:2453-7
13. Bulger JB, Shubrook JH, Snow R. Racial disparities in African Americans with diabetes: process and outcome mismatch. Am J Manag Care 2012; 18:407-13
14. James GD, Baker P, Badrick E, et al. Ethnic and social disparity in glycaemic control in type 2 diabetes; cohort study in general practice 2004-9. J R Soc Med 2012;105:300-8
15. Age-adjusted hospital discharge rates for diabetes as any-listed diagnosis per 1,000 diabetic population, by race, United States, 1988-2009. Centers for Disease Control and Prevention (CDC). 2009. Available at: http://www. cdc.gov/diabetes/statistics/dmany/fig6.htm [Last accessed 17 February 2015]
16. O'Neil SS, Lake T, Merrill A, et al. Racial disparities in hospitalizations for ambulatory care-sensitive conditions. Am J Prev Med 2010;38:381-8
17. Lefebvre KM, Lavery LA. Disparities in amputations in minorities. Clin Orthop Relat Res 2011;469:1941-50
18. Young BA, Maynard C, Reiber G, Boyko EJ. Effects of ethnicity and nephropathy on lower-extremity amputation risk among diabetic veterans. Diabetes Care 2003;26:495-501
19. Feinglass J, Rucker-Whitaker C, Lindquist L, et al. Racial differences in primary and repeat lower extremity amputation: results from a multihospital study. J Vasc Surg 2005;41:823-9
20. Mathieu RAT, Powell-Wiley TM, Ayers CR, et al. Physical activity participation, health perceptions, and cardiovascular disease mortality in a multiethnic population: the Dallas Heart Study. Am Heart J 2012;163:1037-40
21. Shi Q, Zhao Y, Fonseca V, et al. Racial disparity of eye examinations among the U.S. working-age population with diabetes: 2002-2009. Diabetes Care 2014;37:1321-8
22. Tomar SL, Lester A. Dental and other health care visits among U.S. adults with diabetes. Diabetes Care 2000;23:1505-10
23. Percentage of adults aged 18 years or older with diagnosed diabetes receiving a dilated eye exam in the last year, by race/ethnicity, United States, 1994-2010. Centers for Disease Control and Prevention (CDC). 2012. Available at: http://www.cdc.gov/diabetes/statistics/preventive/tneweyeexrace.htm [Last accessed 17 February 2015]
24. Piccolo RS, Pearce N, Araujo AB, McKinlay JB. The contribution of biogeographical ancestry and socioeconomic status to racial/ethnic disparities in type 2 diabetes mellitus: results from the Boston Area Community Health Survey. Ann Epidemiol 2014;24:648-54 e1
25. Karter AJ, Ferrara A, Liu JY, et al. Ethnic disparities in diabetic complications in an insured population. JAMA 2002;287:2519-27
26. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19:327-36
27. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
28. Karim A, Slater M, Bradford D, et al. Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug. J Clin Pharmacol 2007;47:37-47
29. Williams LK, Padhukasahasram B, Ahmedani BK, et al. Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab 2014;99:3160-8
30. Stakos DA, Schuster DP, Sparks EA, et al. Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. Heart 2005;91:589-94
31. Osei K, Schuster DP. Ethnic differences in secretion, sensitivity, and hepatic extraction of insulin in black and white Americans. Diabet Med 1994;11: 755-62
32. Osei K, Rhinesmith S, Gaillard T, Schuster D. Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes. Metabolism 2004; 53:414-22
33. Hiroi S, Sugiura K, Matsuno K, et al. A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes. Diabetes Technol Ther 2013;15:158-65
34. Osei K, Gaillard T, Schuster D. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone. Metabolism 2007;56:24-9
35. Glass LC, Cusi K, Berria R, et al. Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with type 2 diabetes: a double tracer OGTT study. Clin Endocrinol (Oxf) 2010;73:339-45
36. Kikuchi M, Kaku K, Odawara M, et al. Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naive Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks' treatment, comparative study. Curr Med Res Opin 2012;28:1007-16
37. Johnston PS, Feig PU, Coniff RF, et al. Long-term titrated-dose alphaglucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care 1998;21:409-15
38. Johnston PS, Feig PU, Coniff RF, et al. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes Care 1998;21:416-22
39. Narita T, Yokoyama H, Yamashita R, et al. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab 2012;14:283-7
40. Lin BJ, Wu HP, Huang HS, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications 2003;17:179-85
41. Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010;12: 613-22
42. Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009;83:106-16
43. Yang W, Guan Y, Shentu Y, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes 2012;4:227-37
44. Maeda H, Kubota A, Kanamori A, et al. Long-term efficacy and safety of sitagliptin in the treatment of Japanese type 2 diabetes (ASSET-K1) to a target of HbA1c57%. J Endocrinol Invest 2013;36:568-73
45. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32: 1649-55
46. Hermans MP, Delibasi T, Farmer I, et al. Effects of saxagliptin added to submaximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Curr Med Res Opin 2012;28:1635-45
47. Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extendedrelease metformin vs. uptitrating metformin dosage. Diabetes Obes Metab 2012;14:365-71
48. Stenlöf K, Raz I, Neutel J, et al. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin 2010;26:2355-63
49. Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26:540-9
50. Göke B, Gallwitz B, Eriksson J, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010;64:1619-31
51. Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-22
52. Pfützner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011;13:567-76
53. Pan CY, Yang W, Tou C, et al. Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev 2012;28:268-75
54. Thrasher J, Daniels K, Patel S, et al. Efficacy and safety of linagliptin in black/ African American patients with type 2 diabetes: a 6-month, randomized, double-blind, placebo-controlled study. Endocr Pract 2014;20:412-20
55. Friedrich C, Glund S, Lionetti D, et al. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2013;76:445-54
56. Davidson J, Lajara R, Aguilar R, et al. Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials. BMJ Open Diab Res Care 2014;2:e000020
57. Araki E, Kawamori R, Inagaki N, et al. Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2013;15:364-71
58. He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet 2012;51:147-62
59. Pan C, Xing X, Han P, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:737-44
60. Yoshioka K, Isotani H, Ohashi S, Imamura M. Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy. Diabetes Metab Syndr 2013;7:32-4
61. Seino Y, Fujita T, Hiroi S, et al. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin 2011;27(Suppl 3): 21-9
62. Schwartz SL, Ratner RE, Kim DD, et al. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther 2008;30:858-67
63. Forti A, Garcia EG, Yu MB, et al. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes. Curr Med Res Opin 2008;24:2437-47
64. Xu W, Bi Y, Sun Z, et al. Comparison of the effects on glycaemic control and beta-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). J Intern Med 2015 Jan;277(1): 137-50. doi: 10.1111/joim.12293. Epub 2014 Aug 5
65. Li CJ, Li J, Zhang QM, et al. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovasc Diabetol 2012 Nov 15;11:142. doi: 10.1186/1475-2840-11-142
66. Suzuki D, Toyoda M, Kimura M, et al. Effects of liraglutide, a human glucagonlike peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. Intern Med 2013;52:1029-34
67. Yu Pan C, Han P, Liu X, et al. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metab Res Rev 2014;30:726-35
68. Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebocontrolled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012;14:910-17
69. Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab 2014;16:1102-10
70. Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodiumglucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:357-65
71. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147-58
72. Riggs MM, Staab A, Seman L, et al. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. J Clin Pharmacol 2013;53:1028-38
73. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
74. Raebel MA, Ellis JL, Schroeder EB, et al. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study. Pharmacoepidemiol Drug Saf 2014;23:699-710
75. Thorlby R, Jorgensen S, Ayanian JZ, Sequist TD. Clinicians' views of an intervention to reduce racial disparities in diabetes outcomes. J Natl Med Assoc 2011;103:968-77